Document is current
Any future updates will be listed below
-
Authors
Michaux, Kristina D.
Metcalfe, Rebecca K.
Burns, Paloma
Conklin, Annalijn I.
Hoens, Alison M.
Smith, Daniel
Struik, Laura
Safari, Abdollah
Sin, Don D.
Sadatsafavi, Mohsen http://orcid.org/0000-0002-0419-7862
,
Bansback, Nick
Barn, Prabjit
Bottorff, Joan L.
Bryan, Stirling
Carlsten, Chris
De Vera, Mary
Gershon, Andrea
Gupta, Samir
Gustafson, Paul
Mokhtaran, Mehrshad
Johnson, Jim
Joshi, Phalgun
Leung, Janice
Lynd, Larry D.
Simmers, Brian
Sutherland, Janet
Vinay, Dhingra
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (PHT 178432)
- License Information
-
More Information
Article History
Received: 7 June 2022
Accepted: 9 January 2023
First Online: 14 February 2023
Declarations
:
: The phase 1 study has received ethics approval from the UBC’s Behavioral Research Ethics Board (approval number: H21-02348) and site-specific institutional approval from the two participating hospital sites: Providence Health Care for St. Paul’s Hospital and from Vancouver Coastal Health for Vancouver General Hospital. Provisional acceptance for the phase 2 clinical trial for waiver of patient consent for the primary endpoint (medication appropriateness) has been obtained. Ethical approval for the longitudinal component of phase 2 is in progress; prior to enrollment in this component, we will obtain informed written consent from all participants. The phase 2 trial is prospectively registered at , identifier: NCT05309356. All protocol amendments will be subjected to ethics board approval and will be updated in the clinical trial registry accordingly. Written informed consent will be obtained for patient participation.
: Not applicable.
: The authors declare that they have no competing interests.
